Combination Therapy for the Treatment of Diffuse Midline Gliomas
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial determines if the combination of ONC201 with different drugs,
panobinostat or paxalisib, is effective for treating patients with diffuse midline gliomas
(DMGs). Despite years of research, little to no progress has been made to improve outcomes
for patients with DMGs, and there are few treatment options. ONC201, panobinostat, and
paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some
of the enzymes needed for cell growth. This phase II trial assesses different combinations of
these drugs for the treatment of DMGs.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Mithil Prasad Foundation Storm the Heavens Fund The Chad-Tough Defeat DIPG Foundation